Alliance for Cancer Gene Therapy
ACGT funds the best scientists and biotechnology companies harnessing the power of cell and gene therapy to transform how cancer is treated and drive momentum towards a cure. 100% of your donation directly supports research.
ACGT is the only U.S. non-profit dedicated exclusively to advancing cancer cell and gene therapy. We have a track record of success, funding work that has brought an entirely new paradigm of treatment to people with certain deadly cancers. For 20 years, we have funded research into effective, efficient, less toxic cancer therapy using the body’s own genes and cells as medicine. We continue to drive innovative research forward today, funding cutting-edge science from the development of cancer vaccines to cell and gene therapies for brain cancer.
While advances in cancer cell and gene therapy have been truly life changing for an increasing number of patients, there continues to be an unmet need for research into utilizing these therapies in broader cancer types. For instance, the Alliance is committed to addressing the urgent need to translate the success of cell and gene therapies for blood cancers (CAR-T) into therapies to eradicate the most challenging solid tumor cancers.
Your support is critical to helping researchers meet these challenges, while also addressing hurdles such as side effects, cost and complexity of therapy.
We support high-risk, high-reward scientific research into the causes, treatment and prevention of cancer using the body’s own cells and genes as medicine. By accelerating this research, we will help develop therapies for people with all kinds of cancers that are significantly more effective and less toxic than current cancer treatments.
We identify and fund innovative research and clinical trials that meet a rigorous set of scientific standards. This research is carefully vetted for its immediate potential to treat different types of cancers, without as many toxic side effects as traditional surgery, chemotherapy and radiation.
While we fund research touching on all cancers, the Alliance currently focuses on areas that can have the greatest impact for the patients who have the fewest options, as identified by our scientific advisory council. Currently, ACGT is funding research in ovarian, prostate, sarcoma, glioblastoma, melanoma and pancreatic cancers.
Cell and gene therapies are now saving lives of people with otherwise deadly forms of advanced cancer. It is just the tip of the iceberg for a field that has generated so much excitement from researchers and physicians, and so much hope — so quickly – for patients.
Propelling cancer treatment forward by leaps and bounds requires high-risk innovations that challenge traditional boundaries of cancer therapy. That’s why ACGT funds research that has never been done before. We have a history of backing unfunded scientists who have gone on to become pioneers in the field – whose science has led to new treatments with life-saving results for patients. Today, we invest in innovative research across all kinds of cancer cell and gene therapies – research that isn’t getting funded elsewhere.
Research and trials require enormous capital, and with your support, ACGT can realize the next frontier of cell and gene therapy:
- A kinder, gentler approach to cancer therapy.
- A swifter treatment process.
- A first-line therapy option with minimal side effects — available to more people with all types of cancer.
We are the only charity in the country dedicated exclusively to cancer cell and gene therapy. One-hundred percent of every public donation to ACGT goes directly to fund research – our administrative and marketing costs are paid for through a separate fund.
- 2019: ACGT funded researchers developing cell and gene therapies for pediatric sarcoma and prostate cancers.
- 2018: ACGT funded grants to develop new cell and gene therapy treatments for glioblastoma and pancreatic cancers and funded its first clinical trial in ovarian cancer – moving research from bench to bedside.
- 2017: Based on early funding from ACGT, the FDA approved the first gene therapy treatment for cancer in the United States, a CAR T cell therapy for childhood leukemia developed by Dr. Carl June at the University of Pennsylvania.
- $30.7 million has been awarded by ACGT since 2002.
- ACGT has given 60 grants to 54 research fellows representing 36 top institutions in the U.S. and Canada.
Our scientific advisory council, made up of 15 of the leading scientists in cancer cell and gene therapy, oversees our grant award process. We are rigorous in our efforts to seek out the most promising research. We are a Better Business Bureau-accredited charity and Gold-Participant level with GuideStar. We provide audited financial statements upon request. 100% of your donation directly supports research.